Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Steve Fancy who wrote (4587)	6/29/1998 12:19:00 PM
From: Robert L. Ray	Read Replies (1) \| Respond to of 6136

>>>Is most of the news out, or do we expect further news from IMNR yet on Wednesday?<<< By this do you mean IMNR is presenting something at the Geneva conference on Wednesday?... I have been reading comments by others that the IMNR presentation wasn't until Friday.

To: Steve Fancy who wrote (4587)	6/29/1998 12:28:00 PM
From: Peter Singleton	Read Replies (1) \| Respond to of 6136

Steve, I posted the below a couple of days ago, from the Yahoo IMNR thread. There's a symposium held by IMNR and AGPH 6:30 - 8:30am Geneva time Thursday July 2 which will present the HAART vs HAART + Remune results, as well as presentations by leading AIDS researchers. This symposium looks to be very high profile. Although I've bought a few AGPH and IMNR calls in anticipation of a bounce from the symposium and the HAART data, I have no clue what's going to happen with AGPH's price near term. No reaction so far to the Remune deal, none this morning to the Shionogi NNRTI deal ... both of which appear to add fundamental (risk-adjusted) value to the company. Peter GenevaHORSESHOE98 Jun 17 1998 11:04AM EDT Mogoo--I don't think your scenario is that far fetched. "Therapeutic Advances in Immune Reconstitution: Implications of Immune Based Therapies and Combination Antiretroviral Therapy" an official satellite symposium of the 12th World AIDS Conference is sponsored by IMNR and Agouron Pharmaceuticals on July 2 at 6:30am. The agenda is as follows: 6:30-6:35 Welcome and opening remarks - Dr. Ronald Moss, MD (IMNR Dir of Medical and Scientific Affairs, and practicing HIV physician) 6:35-6:50 Chemokines and HIV-1 Disease - Dr. Robert Gallo 6:50-7:05 Immunopathogenesis Giuseppe Panteleo (Was Tony Fauchi's right hand man at NIH, running Switz. trial)), 7:05-7:20 T Helper Immune Responses - Dr. Bruce Walker 7:20-7:45 Effects of HAART Compared to HAART Plus and Immune Based Therapy (REMUNE) on Lymphocyte Proliferative Responses (LPR) to HIV Antigens- Dr. Fred Valentine (This is an early look at Valentine's interim results--Late Breaker is set for July 3 at 10:00) 7:45-8:00 In Vitro Immune Responses to HIV-1 Antigens Dr.Eduardo Fernandez-Cruz (running Spain trial) 8:00-8:15 REMUNE and HIV-Specific Immune Responses- Dr. Ronald Moss 8:15-8:30 Panel Discussion and Audience Questions I understand that IMNR will be prominently featured at the Agouron symposium set for 6:30 on June 29.